- Home
- CBLL vs ALT Comparison
CBLL vs ALT Comparison
Compare CBLL & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBLL
- ALT
- Stock Information
- Founded
- CBLL 2014
- ALT 1997
- Country
- CBLL United States
- ALT United States
- Employees
- CBLL N/A
- ALT N/A
- Industry
- CBLL
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- CBLL
- ALT Health Care
- Exchange
- CBLL Nasdaq
- ALT Nasdaq
- Market Cap
- CBLL 538.0M
- ALT 472.3M
- IPO Year
- CBLL 2024
- ALT N/A
- Fundamental
- Price
- CBLL $16.81
- ALT $5.40
- Analyst Decision
- CBLL Strong Buy
- ALT Strong Buy
- Analyst Count
- CBLL 6
- ALT 7
- Target Price
- CBLL $33.00
- ALT $21.00
- AVG Volume (30 Days)
- CBLL 342.3K
- ALT 2.5M
- Earning Date
- CBLL 05-08-2025
- ALT 05-13-2025
- Dividend Yield
- CBLL N/A
- ALT N/A
- EPS Growth
- CBLL N/A
- ALT N/A
- EPS
- CBLL N/A
- ALT N/A
- Revenue
- CBLL $71,535,000.00
- ALT $20,000.00
- Revenue This Year
- CBLL $34.12
- ALT $4,108.32
- Revenue Next Year
- CBLL $28.66
- ALT $3,900.06
- P/E Ratio
- CBLL N/A
- ALT N/A
- Revenue Growth
- CBLL 44.86
- ALT N/A
- 52 Week Low
- CBLL $10.01
- ALT $3.55
- 52 Week High
- CBLL $32.75
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- CBLL N/A
- ALT 52.71
- Support Level
- CBLL N/A
- ALT $5.38
- Resistance Level
- CBLL N/A
- ALT $5.81
- Average True Range (ATR)
- CBLL 0.00
- ALT 0.35
- MACD
- CBLL 0.00
- ALT -0.03
- Stochastic Oscillator
- CBLL 0.00
- ALT 34.18
About CBLL CeriBell Inc. Common Stock
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.